Imagerie scintigraphique de l’infection des prothèses de hanche et de genou

Fernandez, Philippe; Clermont-Gallerande, Henri de; Dauchy, F.-A.; Massaloux, K.; Dupon, M.

doi:10.1016/j.mednuc.2013.06.001

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The availability of a sterile device, Leukokit®, has absolutely provided an instrument to facilitate the whole procedure, reducing time and assuring sterility as reported in the recent guidelines published by EANM Committee [14]. The utility and safety of Leukokit® were reported in several studies that obtained high values of LE and RY comparable to our study [3, 8–11, 17, 18]. These studies used 99m Tc-HMPAO-WBCs with Leukokit®.…”

Section: Discussionsupporting

confidence: 74%

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Auletta

Riolo

Varani

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

The scintigraphy with radiolabelled autologous leukocytes (WBCs) is considered the gold-standard technique for imaging infections. Leukokit® is a commercially available, disposable, sterile kit for labelling WBCs ex vivo. In this kit, WBCs isolation from red blood cells (RBCs) was performed using poly(O-2-hydroxyethyl)starch (HES) as the RBCs sedimentation agent. Due to its poor availability, HES has been recently replaced by Gelofusine as the RBC sedimentation agent. The aim of this study was to compare the labelling efficiency and the diagnostic accuracy of WBCs labelled with Leukokit® with HES vs Leukokit® with Gelofusine. WBCs were isolated using HES or Gelofusine for 45 minutes and then purified from platelets (PLTs) and labelled with 1.1 ± 0.3 GBq of freshly prepared 99mTc-HMPAO. The following parameters were evaluated: the number and type of recovered WBCs, RBCs contamination, PLTs contamination, vitality of neutrophils, and chemotactic properties of neutrophils. Clinical comparison was performed between 80 patients (33 males; age 67.5 ± 14.2) injected with 99mTc-HMPAO-WBCs, using HES as the sedimentation agent, and 92 patients (38 males; age 68.2 ± 12.8) injected with 99mTc-HMPAO-WBCs using Gelofusine as the sedimentation agent. Patients were affected by prosthetic joint infections, peripheral bone osteomyelitis, or vascular graft infection. We compared radiolabelling efficiency (LE), final recovery yield (RY), and diagnostic outcome based on microbiology or 2-year follow-up. Results showed that HES provides the lowest RBCs and PLTs contamination, but Gelofusine provides the highest WBC recovery. Both agents did not influence the chemotactic properties of WBCs, and no differences were found in terms of LE and RY. Sensitivity, specificity, and accuracy were also not significantly different for WBCs labelled with both agents (diagnostic accuracy 90.9%, CI = 74.9–96.1 vs 98.3%, CI = 90.8–100, for HES and Gelofusine, respectively). In conclusion, Gelofusine can be considered a suitable alternative of HES for WBCs separation and labelling.

show abstract

Section: Discussionsupporting

confidence: 74%

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Auletta

Riolo

Varani

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET is a functional imaging technique that uses a radioactive analog of glucose to assess glucose metabolism in body tissues. In addition to its wellestablished role in oncologic and brain imaging, 18 F-FDG PET is also used in the assessment of infection, inflammation, and more recently, tissue repair [7,10,19,23,25]. 18 F-FDG accumulates in regions proportionally to their glycolytic rate, therefore greater uptake is seen in regions of increased metabolic activity.…”

Section: Introductionmentioning

confidence: 99%

PET/MRI reveals ongoing metabolic activity in ACL grafts one year post-ACL reconstruction

Korbin¹,

Salerno²,

Achonu³

et al. 2020

J EXP ORTOP

View full text Add to dashboard Cite

Purpose: To use serial PET/MRI imaging to radiographically evaluate the metabolic activity of the ACL graft over the first post-operative year. Methods: Six patients undergoing primary ACL reconstruction were recruited in this prospective study in an inpatient university hospital. All patients underwent femoral and tibial suspensory cortical fixation with quadrupled semitendinosus autograft hamstring ACL reconstruction by an orthopaedic surgeon. Simultaneous 18 F-FDG PET and MRI of both the operative and non-operative knee was performed at three, six, and 12 months post-operatively. Quantification of the mean standardized uptake value (SUV) within the whole-knee, as well as tibial tunnel, femoral tunnel, and intra-articular graft regions of interest (ROIs). Results: PET whole-knee activity was increased at all time-points post-operatively compared to the control, nonoperative knee. Activity decreased over time, yet considerable generalized activity remained 1 year post-operatively, with relative intensity 34% percent higher than control. When the operative knee was divided into three wholeregions, there was greater activity in the tibia at three than 12 months, the femur at six than 12 months, and in the tibia compared to the intra-articular region at 3 months. When they were separated into sub-regions, results demonstrated greater activity closer to the joint surface. Conclusions: PET/MRI evaluation of ACL graft reconstructions demonstrates evolving biologic activity within the graft and both tunnels. Focal areas of increased activity within the tunnels may indicate of ligamento-osseous morphologic changes. These data suggest that graft incorporation continues well beyond 1 year post-operatively. Level of evidence: Level IV.

show abstract

Imagerie scintigraphique de l’infection des prothèses de hanche et de genou

Cited by 2 publications

References 39 publications

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

PET/MRI reveals ongoing metabolic activity in ACL grafts one year post-ACL reconstruction

Contact Info

Product

Resources

About

Imagerie scintigraphique de l’infection des prothèses de hanche et de genou

Cited by 2 publications

References 39 publications

Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

PET/MRI reveals ongoing metabolic activity in ACL grafts one year post-ACL reconstruction

Contact Info

Product

Resources

About

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Labelling and Clinical Performance of Human Leukocytes Labelled with ^99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent